Streetbeat News

Products Services

RKLB

Rocket Lab has announced a last-minute Electron launch for a commercial mission, marking its fastest turnaround from contract to launch in less than two months. This will be Rocket Lab's 12th launch of 2024, continuing its record of increasing annual launches.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 8:32 pm

STLD

Steel Dynamics is optimistic about the 2025 metal market dynamics based on domestic steel demand fundamentals.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 8:31 pm

INCY

Incyte has received Health Canada approval for its OPZELURA (Ruxolitinib) cream, marking it as the first topical JAK inhibitor approved for atopic dermatitis and the first treatment for repigmentation of nonsegmental vitiligo in Canada.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 8:27 pm

IYR

VNQ

XLRE

Floyd Mayweather is investing $402 million in a 1,000-unit affordable housing portfolio in NYC, potentially benefiting from tax breaks. Real estate ETFs like IYR, VNQ, and XLRE saw gains following the news.

Portfolio Pulse from Anthony Noto

October 16, 2024 | 8:25 pm

CERS

Cerus shares declined following updates on its INTERCEPT red blood cell programs in the US and Europe.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 8:24 pm

PLTR

The article discusses recent options trading trends for Palantir Technologies (NYSE:PLTR), highlighting a bullish sentiment among large investors. A significant portion of trades are calls, indicating expectations of a price increase. The predicted price range for PLTR is between $13.0 and $60.0. Currently, PLTR is trading at $41.89, down by 1.27%, with an RSI suggesting it may be approaching overbought territory. Earnings are anticipated in 19 days.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 8:16 pm

GKOS

Glaukos announced that its Phase 3 confirmatory trial for Epioxa met the primary efficacy endpoint and demonstrated a favorable safety profile over 12 months.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 8:14 pm

ACAD

Acadia Pharmaceuticals has received approval from Health Canada for DAYBUE, a treatment for Rett Syndrome. This approval marks a significant milestone for the company, potentially expanding its market reach and revenue opportunities.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 8:09 pm

SPRO

Spero Therapeutics presented in vitro data at IDWeek 2024, demonstrating that SPR719 has a low propensity for resistance development in NTM-PD MAC strains. This highlights the potential of SPR720 for prolonged combination regimens.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 8:08 pm

CBLL

Ceribell's point-of-care EEG technology has been shown to reduce hospital stays and improve functional outcomes compared to conventional EEGs. This was highlighted in five abstracts at the 2024 Neurocritical Care Society Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 8:07 pm